Investment
Features
FeesSafety
Academy
More
Pluang+

Compare YieldMax AMZN Option Income Strategy ETF (AMZY) vs Boston Scientific Corporation (BSX) Price & Performance

YieldMax AMZN Option Income Strategy ETFTrade
Boston Scientific CorporationTrade

Price performance (Past 24H)

Key statistics

YieldMax AMZN Option Income Strategy ETF vs Boston Scientific Corporation — how do they compare? YieldMax AMZN Option Income Strategy ETF trades at $11.27, while Boston Scientific Corporation trades at $51.58 (market cap $74.19B). Which is the better fit depends on your goals.

AMZYBSX
Sector
Income / Options OverlayHealth
52-Week High
$15.75$108.14
52-Week Low
$9.98$42.63
Market Cap
$74.19B
Enterprise Value
$86.27B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

YieldMax AMZN Option Income Strategy ETF

AMZY trades at $11.29, down 2.84% on the day, with a bullish technical signal from moving averages but neutral oscillators. The ETF provides weekly dividend distributions, with recent payouts ranging from $0.06 to $0.14, supporting high yield but raising sustainability concerns. Key support is at $11, with resistance at $12, as the RSI indicates potential overbought conditions near-term.

The outlook for AMZY hinges on its ability to maintain high dividend yields without eroding net asset value. Risks include NAV erosion from its synthetic option strategy and underperformance versus Amazon stock. Analyst sentiment is cautious due to structural drawbacks, making it suitable only for income-focused investors aware of the trade-offs.

Boston Scientific Corporation

Boston Scientific (BSX) trades at $51.66, up 2.38% today, showing strong momentum with three consecutive quarterly earnings beats. The stock maintains bullish technical signals with moving averages supporting upward movement, though oscillators indicate potential overbought conditions. Fundamentally, BSX demonstrates robust growth with 2025 revenue reaching $20.07B and net income margin expanding to 14.43%, supported by strong cash flow generation of $1.54B in 2025.

The outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target offering 30% upside potential. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with recent guidance cuts. Insider buying by the CEO and director signals management confidence in the company's long-term prospects despite near-term challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About YieldMax AMZN Option Income Strategy ETF

AMZY is an actively managed ETF that seeks to generate monthly income by selling call options on Amazon (AMZN) stock. It aims to provide high yield while maintaining exposure to the price movements of the e-commerce giant.

Read more on AMZY

About Boston Scientific Corporation

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Read more on BSX